标题: Bristol-Myers Squibb to Present New Data Demonstrating [打印本页] 作者: liver411 时间: 2011-10-2 04:39 标题: Bristol-Myers Squibb to Present New Data Demonstrating
本帖最后由 风雨不动 于 2012-4-14 14:48 编辑
Bristol-Myers Squibb to Present New Data Demonstrating Company's Leadership in Liver Disease at The Liver Meeting(R) //AASLD Annual Meeting
Sept. 30, 2011, 11:19 a.m. EDT
Bristol-Myers Squibb to Present New Data Demonstrating Company's Leadership
in Liver Disease at The Liver Meeting(R) / AASLD Annual Meeting Oral
presentation on BARACLUDE(R) (entecavir) reinforces continued clinical
development commitment in hepatitis B
PRINCETON, N.J., Sep 30, 2011 (BUSINESS WIRE) -- --Oral presentations on
hepatitis C investigational compounds BMS-790052 and BMS-650032 demonstrate
advancement of robust pipeline
--Breadth of data highlights Company's commitment to pursuing research that
aims to improve the management of liver disease
Bristol-Myers Squibb Company /quotes/zigman/220498/quotes/nls/bmy BMY
+0.84% announced today that 22 abstracts on the Company's research in liver
disease have been accepted for presentation at The Liver Meeting(R) 2011,
the 62nd annual meeting of the American Association for the Study of Liver
Diseases (AASLD), in San Francisco, November 4 - 8. Bristol-Myers Squibb is
advancing a portfolio of compounds that has the potential to address unmet
medical needs for patients with liver disease, including BARACLUDE(R)
(entecavir) for chronic hepatitis B (CHB), and the investigational
compounds BMS-790052, BMS-650032 and PEG-Interferon lambda (Lambda) for
hepatitis C (HCV) and brivanib for hepatocellular carcinoma (HCC).
Key presentations include an oral presentation on BARACLUDE monotherapy vs.
combination therapy for CHB and two oral presentations of Phase II data on
the Company's investigational HCV direct-acting antivirals (DAAs). These
presentations will highlight:
-- The first data from the BE-LOW study, a Phase IIIb comparative study of
BARACLUDE plus tenofovir vs. BARACLUDE monotherapy in treatment-naive
adults with CHB
-- The first results from a Phase IIb study of the NS5A replication complex
inhibitor BMS-790052 plus peginterferon alfa and ribavirin (alfa/RBV) in
treatment-naive HCV genotype 1 and 4 patients, evaluating virologic
response through 12 weeks on treatment (eRVR)
-- The first results of a Phase IIa study of the dual DAA regimen of
BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype
1b-infected patients who have not responded to prior alfa/RBV therapy (null
responders), evaluating sustained virologic response 12 weeks
post-treatment (SVR12)
"Bristol-Myers Squibb is at the forefront of innovation in researching the
treatment of liver diseases. In hepatitis C, where there remain
considerable unmet medical needs, our goal is to increase treatment options
for patients by developing a portfolio of compounds with different
mechanisms of action," said Brian Daniels, MD, senior vice president,
Global Development and Medical Affairs, Research and Development,
Bristol-Myers Squibb. "The data we are presenting at the Liver Meeting help
to expand our understanding of the potential efficacy and safety profiles
of these investigational compounds and support the recent initiation of a
broad Phase III development program in HCV."
The Company will also present new data that further describe the
mechanistic and clinical profile of Lambda, and real-world data that add to
the understanding of the prevalence of and current treatment patterns in
HBV, HCV and HCC, including an oral presentation of data from the BRIDGE
study in HCC. The BRIDGE study is designed to develop global understanding
of HCC, including assessment of treatment by geography and etiology, and
associated clinical outcomes.
The complete list of Bristol-Myers Squibb data presentations is located at: